Zinc Fingers nuclease News and Research

RSS
Researchers develop first non-human primate X-SCID models using genome editing techniques

Researchers develop first non-human primate X-SCID models using genome editing techniques

Scientists develop genetically engineered T cells with fusion inhibitor to disrupt HIV's harpoon

Scientists develop genetically engineered T cells with fusion inhibitor to disrupt HIV's harpoon

Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

BioReliance inks non-exclusive license agreement with QTS for proprietary B-CLEAR technology

BioReliance inks non-exclusive license agreement with QTS for proprietary B-CLEAR technology

BeiGene chooses SAFC's CHOZN Platform to support oncology drug development

BeiGene chooses SAFC's CHOZN Platform to support oncology drug development

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

MGH investigators develop next-generation genome editing system

MGH investigators develop next-generation genome editing system

Horizon Discovery, Sirion Biotech ink supply and distribution agreement

Horizon Discovery, Sirion Biotech ink supply and distribution agreement

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Sigma Life Science signs license agreement with Horizon Discovery for CompoZr ZFN technology

Sigma Life Science signs license agreement with Horizon Discovery for CompoZr ZFN technology

Sigma Life Science releases genome editing tool for screening and exploratory studies

Sigma Life Science releases genome editing tool for screening and exploratory studies

Discovery provides evidence that genetic defect responsible for Down syndrome can be suppressed

Discovery provides evidence that genetic defect responsible for Down syndrome can be suppressed

Sangamo BioSciences fourth quarter revenues increase to $8.9 million

Sangamo BioSciences fourth quarter revenues increase to $8.9 million

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Safer alternative to experimental gene therapy against HIV infection

Safer alternative to experimental gene therapy against HIV infection

Sigma-Aldrich acquires BioReliance

Sigma-Aldrich acquires BioReliance

Sangamo BioSciences starts Phase 2 clinical studies to develop functional cure for HIV/AIDS

Sangamo BioSciences starts Phase 2 clinical studies to develop functional cure for HIV/AIDS

Nature publishes Sangamo's gene correction strategy for A1AT deficiency

Nature publishes Sangamo's gene correction strategy for A1AT deficiency